Prostate carcinoma (PC-3) cell proliferation is stimulated by the 22–25-kDa proteolytic fragment (1–160) and inhibited by the 16-kDa fragment (1–95) of recombinant human insulin-like growth factor binding protein-3

https://doi.org/10.1016/S1096-6374(98)80324-9Get rights and content

Summary

In a previous study, the biphasic effect of increasing dosages of recombinant human insulin-like growth factor binding protein-3 (rhlGFBP-3) on proliferation in the prostate carcinoma PC-3 cell line (stimulation followed by depression) was shown to reflect changes in the bioavailability of IGF-II secreted by the cells, IGF-II being the major factor responsible for their autocrine growth. These changes depend on the extent of IGFBP-3 proteolysis induced by serine proteases, in particular, plasmin. In order to examine the mechanism of action of IGFBP-3, we investigated the effects of its two major fragments isolated by HPLC following limited proteolysis by plasmin in vitro. The predominant fragment with an apparent molecular mass of 22–25 kDa in SDS-PAGE (under non-reducing conditions) had previously been shown to retain weak affinity for IGFs, whereas the other fragment of 16 kDa lost all such affinity. From their recently determined amino acid sequences, these fragments correspond to the first 160 and 95 residues, respectively, of IGFBP-3. 0.5–5 nM intact rhlGFBP-31–264, when pre-incubated with 5 nM rhlGF-II, dose-dependently inhibited (up to 100%) its mitogenic effect, via sequestration owing to its strong affinity for IGF-II. The same concentrations of the larger fragment (IGFBP-31–160) elicited only weak inhibition (up to 30%), coherent with its weak affinity. The smaller fragment (IGFBP-31–95) provoked total inhibition despite its lack of affinity for IGFs and therefore by an IGF-independent mechanism. PC-3 cells in serum-free medium were weakly stimulated by 5 nM intact IGFBP-3. This had previously been shown to be related to its proteolysis and the ratio of proteolysed to intact IGFBP-3. At the same concentration, IGFBP-31–160 stimulated this proliferation by a factor of 5–7, whereas IGFBP-31–95 totally suppressed it. 5 nM IGFBP-31–95 inhibited the mitogenic action of 1% fetal calf serum by 80%, but by only 25% in the presence of an antibody blocking the type 1 IGF receptor. Its inhibition is therefore exerted principally, but not exclusively, via the IGF signalling pathway. Our data indicate that the IGFBP-3 fragments composed of residues 1–160 and 1–95 are biologically active on PC-3 cells and that their opposite actions may account for the events observed when IGFBP-3 is proteolysed in the cell environment. These proteolytic fragments may therefore play a role in the development of prostate adenocarcinomas in vivo.

References (12)

There are more references available in the full text version of this article.

Cited by (24)

  • Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells

    2002, Journal of Biological Chemistry
    Citation Excerpt :

    Candidate IGFBP-3 receptors include the type V TGF-β receptor or a related serine-threonine kinase receptor (34, 64), and other proteins in cell lysates and membranes that bind IGFBP-3 (4, 30, 36, 65). IGFBP-3 signaling has been proposed to involve phosphorylation of Smad2 and Smad3 (11), nuclear localization (6, 66-70), and proteolysis (31, 71,72). Smad2 and Smad3, signaling molecules downstream from the TGF-βI receptor that function as transcription comodulators (73), were increased in anti-phosphoserine immunoprecipitates of lysates from IGFBP-3-treated T47D breast cancer cells (11).

  • Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-β1 signaling

    2002, Journal of Biological Chemistry
    Citation Excerpt :

    For example, plasminogen binds to IGFBP-3 in vivo, an interaction proposed to lead to IGFBP-3 proteolysis (15). Plasmin-derived IGFBP-3 fragments can exert both inhibitory and stimulatory effects on cell proliferation and show greatly decreased IGF binding, Thus, plasmin proteolysis of IGFBP-3 can regulate IGF bioavailability (42). IGF-I in turn decreases plasminogen activity in cell-conditioned medium (16), suggesting a complex regulatory loop.

  • A non-IGF binding mutant of IGFBP-3 modulates cell function in breast epithelial cells

    2002, Biochemical and Biophysical Research Communications
    Citation Excerpt :

    These effects of IGFBP-3 can vary between different cells and within a cell type depending on the concentration of IGFBP-3 as determined in the MCF-10A cells. A major mechanism affecting IGFBP-3 is its limited proteolysis which it undergoes in biological fluids and in cell culture media [30] and which generates different fragments that might be biologically active [31]. Originally, it was considered that proteolysis lowered the affinity of IGF binding and was therefore a mechanism for modulating IGF availability.

View all citing articles on Scopus
View full text